Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcherโs laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.
์ข
๋ชฉ ์ฝ๋ SEER
ํ์ฌ ์ด๋ฆSeer Inc
์์ฅ์ผDec 04, 2020
CEOFarokhzad (Omid C)
์ง์ ์134
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃDec 04
์ฃผ์3800 Bridge Parkway, Suite 102
๋์REDWOOD CITY
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ94065
์ ํ16504530000
์น์ฌ์ดํธhttps://seer.bio/
์ข
๋ชฉ ์ฝ๋ SEER
์์ฅ์ผDec 04, 2020
CEOFarokhzad (Omid C)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์